Cyclodextrin Modified Block Polymer for Oral Chemotherapy

Cationic polymers have received much attention for their potential use as nonviral gene delivery agents. Under certain conditions, these polymers self-assemble with poly(nucleic acids) via electrostatic interactions and condense them into submicron size particles that can be endocytosed by cells. Many drugs are commercially available for cancer treatment but most of them lacks in terms of poor solubility thereby resulting in inappropriate treatment. This research was planned and tested to ensure the preservation of product safety in our body for enhancing bioactivity of hybrid cyclodextrine nano-capsules, wherein cyclodextrin molecules are modified with Poly(e-Caprolactone)-Poly(Ethylene Glycol) (PCL-PEG), wherein nanocapsules were prepared from cyclodextrin and further were coated with PCL-PEG for enhancing cellular uptake and interacting with biological films in order to provide drug delivery of anti-cancer agent i.e. camptothecin. The nanocapsules were then further subjected to characterization studies which comprises zeta potential, drug release profiles, in-vitro toxicity and transfection effectiveness.